Rafael Holdings, Inc. (RFL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rafael Holdings, Inc. (RFL) has a cash flow conversion efficiency ratio of -0.090x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.51 Million) by net assets ($83.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RFL market cap for the company's overall valuation and market capitalisation.
Rafael Holdings, Inc. - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Rafael Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rafael Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rafael Holdings, Inc. ranked by their cash flow conversion efficiency. Explore Rafael Holdings, Inc. cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MagnaChip Semiconductor
NYSE:MX
|
-0.020x |
|
Zuari Agro Chemicals Limited
NSE:ZUARI
|
0.202x |
|
M & A EQUITY HOLDINGS BERHAD
KLSE:7082
|
-0.069x |
|
Bertrandt Aktiengesellschaft
XETRA:BDT
|
0.156x |
|
Sound Financial Bancorp Inc
NASDAQ:SFBC
|
0.018x |
|
Kino Polska TV SA
WAR:KPL
|
0.081x |
|
Mobile Infrastructure Corporation
NASDAQ:BEEP
|
-0.010x |
|
Korea Petroleum Industries Co
KO:004090
|
0.021x |
Annual Cash Flow Conversion Efficiency for Rafael Holdings, Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Rafael Holdings, Inc. from 2016 to 2025. View Rafael Holdings, Inc. (RFL) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | $98.37 Million | $-18.92 Million | -0.192x | -112.69% |
| 2024-07-31 | $86.26 Million | $-7.80 Million | -0.090x | +19.71% |
| 2023-07-31 | $96.63 Million | $-10.89 Million | -0.113x | +58.01% |
| 2022-07-31 | $97.21 Million | $-26.08 Million | -0.268x | -135.09% |
| 2021-07-31 | $136.70 Million | $-15.60 Million | -0.114x | -219.25% |
| 2020-07-31 | $130.53 Million | $-4.67 Million | -0.036x | -42.40% |
| 2019-07-31 | $124.76 Million | $-3.13 Million | -0.025x | -59.84% |
| 2018-07-31 | $115.56 Million | $-1.81 Million | -0.016x | +39.93% |
| 2017-07-31 | $62.08 Million | $-1.62 Million | -0.026x | -1872.49% |
| 2016-07-31 | $48.81 Million | $72.00K | 0.001x | -- |
About Rafael Holdings, Inc.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells… Read more